According to the recent Institute of Medicine (IOM) report on Relieving Pain in America (2011), chronic pain is a public health epidemic affecting more than 116 million Americans and costing more than $600 billion per year in healthcare expenses and lost work productivity. More Americans suffer from pain than those afflicted with heart disease, diabetes and cancer combined. Despite recent advances in treatment, most patients do not obtain adequate pain relief. Because we do not fully understand the mechanisms underlying chronic pain development and persistence, new approaches that take into account comorbid pain conditions and genomics are needed. The primary mission of our Center is to significantly advance the science underlying the genomic mechanisms of pain so that new drug targets can be elucidated and novel therapeutic interventions can be tested to eradicate pain. The conceptual basis for this core acknowledges that nociception (neural processing of noxious stimulation) and pain (unpleasant emotional experience) are multifactorial and that co-morbidities, for example depression, anxiety, stress, and fear, significantly influence these processes (Figure 1 (Maixner et al., 2011). This stance is further supported in a recent review in which Mogil (2009) argues that rodent models of pain should be tested not just for nocifensive behaviors, but also for pain-affected phenomena such as cognition, depression, fear and anxiety. The same argument holds true when examining clinical chronic pain phenotypes (Diatchenko et al., 2006). The overarching mission of the Translational Phenotyping Core (TPC) is to provide services and support for rodent or clinical behavioral phenotyping and sample collection and processing. To achieve this mission, we propose the following aims:
Aim 1. Support the collection, analysis, interpretation and dissemination of behavioral data for the four pilot studies included in the Center proposal as well as new studies as they arise. The core service capacity includes rodent and clinical testing equipment that will provide a wide range of phenotyping assays, including pain/nocifensive testing and assessment of depression, anxiety, fear and other comorbid pain conditions. In addition, although not proposed for the current pilot studies, equipment and resources are available for new pilot studies that will require assessment of plasticity in the spinal cord dorsal horn via electrophysiological recording and evaluation of gait disturbances.
Aim 2. Promote interdisciplinary collaborations between basic, translational and clinical scientists involved in pain research through increased access to comprehensive services. Initially, this Core will primarily serve the Center pilot PIs. We envision that as we publish and market our core phenotyping services, utilization by interdisciplinary colleagues will increase and new collaborations will be formed to further accelerate pain research on campus.
Aim 3. Acquire, maintain, and upgrade equipment and resources that can be used to support existing and future studies of pain. With expanded use, particularly by colleagues from various disciplines, we anticipate that user requests will necessitate the purchase of new equipment that can be used to supply additional assays that more completely address the pain phenotype. The core directors will survey the campus community and core users annually to determine user needs and obtain needed equipment. In addition, the core directors will keep detailed logs of service and maintenance contracts on each piece of equipment and calibrate instruments as needed.

Agency
National Institute of Health (NIH)
Institute
National Institute of Nursing Research (NINR)
Type
Center Core Grants (P30)
Project #
1P30NR014129-01
Application #
8471335
Study Section
Special Emphasis Panel (ZNR1-REV-M (12))
Project Start
Project End
Budget Start
2012-09-27
Budget End
2013-06-30
Support Year
1
Fiscal Year
2012
Total Cost
$24,419
Indirect Cost
$8,511
Name
University of Maryland Baltimore
Department
Type
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Hertz, Daniel L; Owzar, Kouros; Lessans, Sherrie et al. (2016) Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res 22:4890-4900
Wu, Junfang; Zhao, Zaorui; Kumar, Alok et al. (2016) Endoplasmic Reticulum Stress and Disrupted Neurogenesis in the Brain Are Associated with Cognitive Impairment and Depressive-Like Behavior after Spinal Cord Injury. J Neurotrauma 33:1919-1935
Wu, Junfang; Zhao, Zaorui; Zhu, Xiya et al. (2016) Cell cycle inhibition limits development and maintenance of neuropathic pain following spinal cord injury. Pain 157:488-503
Starkweather, Angela R; Heineman, Amy; Storey, Shannon et al. (2016) Methods to measure peripheral and central sensitization using quantitative sensory testing: A focus on individuals with low back pain. Appl Nurs Res 29:237-41
Starkweather, Angela R; Ramesh, Divya; Lyon, Debra E et al. (2016) Acute Low Back Pain: Differential Somatosensory Function and Gene Expression Compared With Healthy No-Pain Controls. Clin J Pain 32:933-939
Redeker, Nancy S; Anderson, Ruth; Bakken, Suzanne et al. (2015) Advancing Symptom Science Through Use of Common Data Elements. J Nurs Scholarsh 47:379-88
Colagiuri, B; Schenk, L A; Kessler, M D et al. (2015) The placebo effect: From concepts to genes. Neuroscience 307:171-90
Lipinski, Marta M; Wu, Junfang; Faden, Alan I et al. (2015) Function and Mechanisms of Autophagy in Brain and Spinal Cord Trauma. Antioxid Redox Signal 23:565-77
Ellero-Simatos, Sandrine; Beitelshees, Amber L; Lewis, Joshua P et al. (2015) Oxylipid Profile of Low-Dose Aspirin Exposure: A Pharmacometabolomics Study. J Am Heart Assoc 4:e002203
Grimm, P Richard; Lazo-Fernandez, Yoskaly; Delpire, Eric et al. (2015) Integrated compensatory network is activated in the absence of NCC phosphorylation. J Clin Invest 125:2136-50

Showing the most recent 10 out of 12 publications